Penchala Mittadodla, MD
Pulmonary Disease · Rogers, ARNPI 1720219397
Payments from drug & device makers
What this record shows
The money is spread across several categories — education (47.5%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Intuitive Surgical accounts for 72.3% of it on its own, with 42 other manufacturers making up the rest. Reporting peaked in 2024 at $16,136 and has fallen 89.8% since, to $1,651 in 2025. Among pulmonary disease clinicians in AR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 290 payments — averaging $74.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$16K
- AstraZeneca$688
- Actelion Pharmaceuticals US, Inc.$490
- GSK$435
- Boehringer Ingelheim$429
- Amgen$396
- plus $4K from 37 others
What the payments were for
- Travel & lodging$4,46721%
- Food & beverage$6,80132%
- Education$10,21148%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$14,849
- KRYSTEXXA$125
- AeroEclipse$124
- XARELTO$122
- ALIYA SYSTEM$121
- TYVASO$121
- Repatha$121
- FABRAZYME$121
- CEREZYME$121
- CERDELGA$121
- ALDURAZYME$121
- LUMIZYME$121
- ULTOMIRIS$116
How this compares
$21,479 in reported general payments places this provider in the 95th percentile of 102 pulmonary disease providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrikaftaElexacaftor/Tezacaftor/Ivacaft | 53 | $1,535,238 |
| UptraviSelexipag | 12 | $268,248 |
| OfevNintedanib Esylate | 20 | $259,931 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 69 | $59,463 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 32 | $25,884 |
| Spiriva RespimatTiotropium Bromide | 29 | $15,689 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 31 | $14,452 |
| Breo ElliptaFluticasone/Vilanterol | 31 | $13,648 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 16 | $7,510 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 161 | $4,628 |
| Incruse ElliptaUmeclidinium Bromide | 13 | $4,526 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 15 | $2,130 |
| Levalbuterol Tartrate HfaLevalbuterol Tartrate | 13 | $694 |
| Montelukast Sodium | 96 | $524 |
| Fluticasone Propionate | 38 | $455 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat | $429 | $283,12965 claims |
| Actelion Pharmaceuticals US, Inc.Uptravi | $490 | $268,24812 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta | $435 | $92,088144 claims |
| AstraZenecaBreztri Aerosphere | $688 | $25,88432 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 102 pulmonary disease providers in Arkansas.
Other pulmonary disease in Rogers
- Daniel PaulRogers$244K
- Jason McKinneyRogers$86K
- Glauber PereiraRogers$11K
- Junaid KhanRogers$6K
- Kevin MeredithRogers$5K
- Amer RazaRogers$5K
- Ladly AbrahamConway$371K
- Arturo MeadeFort Smith$67K
- Nikhil MeenaLittle Rock$63K
- Mark SiffordJonesboro$20K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.